A case study evaluation of ethics review systems for multicentre clinical trials

Medical Journal of Australia

Volumn 191, Issue 5, 2009, Pages 280-282

  Hicks, Sian C ^a   Rebecca , E James ^b   Wong, Nicole ^b   Tebbutt, Niall C ^c   Wilson, Kate ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRIVANIB; CAPECITABINE; CETUXIMAB; MITOMYCIN C; PLACEBO;

ARTICLE; AUSTRALIA; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; METASTASIS; PROFESSIONAL STANDARD; RESEARCH ETHICS;

EID: 77952296590     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02786.x     Document Type: Article

References (12)

1. National Health and Medical Research Council. National statement on ethical conduct in human research. Canberra: NHMRC, 2007. http://www.nhmrc.gov. au/PUBLICATIONS/synopses/-files/e72.pdf (accessed Jul 2009).
2. Fox RM. Debate: should Australia move towards a centralized ethics committees system? The case for. Intern Med J 2005; 35: 247-248. (Pubitemid 40529587)
3. Roberts LM, Bowyer L, Homer CS, Brown MA. Multicentre research: negotiating the ethics approval obstacle course [letter]. Med J Aust 2004; 180: 139. (Pubitemid 38173111)
4. Whiteman DC, Webb PM, Purdie DM, Green AC. National ethics committee urgently needed. Med J Aust 2003; 178: 187. (Pubitemid 36342336)
5. Christie DRH, Gabriel GS, Dear K. Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? Intern Med J 2007; 37: 680-686. (Pubitemid 47481156)
6. Poustie SJ, Taylor DM, Forbes AB, et al. Implementing a research governance framework for clinical and public health research. Med J Aust 2006; 185: 623-626. (Pubitemid 46070939)
7. New South Wales Department of Health. Research - authorisation of proposals to conduct research on humans within NSW public health system. Policy directive PD2007-043, 18 July 2007, file no. 05/1874-4. http://www.health. nsw.gov.au/policies/pd/2007/PD2007-043.html (accessed Aug 2009).
8. ClinicalTrials.gov (US National Institutes of Health). The MAX Study: a randomised phase II/III study to evaluate the role of mitomycin C, avastin and xeloda in patients with untreated metastatic colorectal cancer. (ClinicalTrials.gov identifier NCT00294359; Australian and New Zealand Cl i n ical Tria l s Registry No. ACTRN012605000025639.) http://clinicaltrials. gov/ct2/show/NCT00294359 (accessed Aug 2009).
9. ClinicalTrials.gov (US National Institutes of Health). A phase III randomized study of brivanib alaninate (BMS-582664) in combination with cetuximab (Erbitux) versus placebo in combination with cetuximab (Erbitux) in patients previously treated with combination chemotherapy for metastatic colorectal carcinoma. (ClinicalTrials. gov identifier NCT00640471; Australian and New Zealand Clinical Trials Registry No. ACTRN12607000589482.) http://clinicaltrials.gov/ ct2/show/NCT00640471 (accessed Aug 2009).
10. Fitzgerald MH, Phillips PA. Centralized and non-centralized ethics review: a five nation study. Account Res 2006; 13: 47-74.
11. Chaddah MR. The Ontario Cancer Research Ethics Board: a central REB that works. Curr Oncol 2008; 15: 49-52.
12. Christian MC, Goldberg JL, Killen J, et al. A central institutional review board for multi-institutional trials. N Engl J Med 2002; 346: 1405-1408. (Pubitemid 34754617)